论文部分内容阅读
急性冠状动脉综合征(ACS)是当今工业化发达国家以及我国心血管疾病的主要死因之一。血小板在ACS的发生、发展过程中起着关键作用,所以在冠心病的二级预防以及ACS患者的治疗中,抗血小板治疗具有极其重要的地位。近年来,临床常用的抗血小板药物主要为环氧化酶抑制剂、ADP受体抑制剂和血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂。各类药物单独或联合应用时ACS患者的预后有所区别,选择最佳的药物组合以及新药的研究都将不断改善ACS的治疗现状。
Acute coronary syndrome (ACS) is one of the major causes of cardiovascular disease in industrialized countries and in our country today. Platelets play a key role in the development and progression of ACS. Therefore, antiplatelet therapy plays an important role in the secondary prevention of coronary heart disease and the treatment of ACS patients. In recent years, clinical antiplatelet drugs are mainly cyclooxygenase inhibitors, ADP receptor inhibitors and platelet glycoprotein Ⅱ b / Ⅲ a receptor antagonist. The prognosis of patients with ACS is different when all kinds of drugs are used alone or in combination. The selection of the best combination of drugs and new drug research will continue to improve the treatment status of ACS.